Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 107204907 | 10720490 | 7 | F | 20100227 | 20160907 | 20150119 | 20160913 | EXP | PHHY2010CA13505 | SANDOZ | 64.11 | YR | F | Y | 0.00000 | 20160913 | CN | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 107204907 | 10720490 | 1 | SS | SANDOSTATIN LAR DEPOT | OCTREOTIDE ACETATE | 1 | Intramuscular | 30 MG, QMO | U | 0 | 30 | MG | /month | ||||||
| 107204907 | 10720490 | 2 | SS | SANDOSTATIN | OCTREOTIDE ACETATE | 1 | Subcutaneous | UNK UNK, BID | 0 | BID | |||||||||
| 107204907 | 10720490 | 3 | PS | METOPROLOL. | METOPROLOL | 1 | Unknown | U | 73288 | ||||||||||
| 107204907 | 10720490 | 4 | C | HYDROCHLOROTHIAZIDE. | HYDROCHLOROTHIAZIDE | 1 | Unknown | U | 0 | ||||||||||
| 107204907 | 10720490 | 5 | C | AVAPRO | IRBESARTAN | 1 | Unknown | U | 0 | ||||||||||
| 107204907 | 10720490 | 6 | C | CLONIDINE. | CLONIDINE | 1 | Unknown | U | 0 | ||||||||||
| 107204907 | 10720490 | 7 | C | CRESTOR | ROSUVASTATIN CALCIUM | 1 | Unknown | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 107204907 | 10720490 | 1 | Carcinoid tumour |
| 107204907 | 10720490 | 2 | Carcinoid tumour |
| 107204907 | 10720490 | 3 | Product used for unknown indication |
| 107204907 | 10720490 | 4 | Product used for unknown indication |
| 107204907 | 10720490 | 5 | Product used for unknown indication |
| 107204907 | 10720490 | 6 | Product used for unknown indication |
| 107204907 | 10720490 | 7 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 107204907 | 10720490 | HO |
| 107204907 | 10720490 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 107204907 | 10720490 | Asthenia | |
| 107204907 | 10720490 | Diarrhoea | |
| 107204907 | 10720490 | Endometrial thickening | |
| 107204907 | 10720490 | Gait disturbance | |
| 107204907 | 10720490 | Haemoglobin decreased | |
| 107204907 | 10720490 | Injection site erythema | |
| 107204907 | 10720490 | Injection site mass | |
| 107204907 | 10720490 | Injection site swelling | |
| 107204907 | 10720490 | Injection site warmth | |
| 107204907 | 10720490 | Malaise | |
| 107204907 | 10720490 | Nausea | |
| 107204907 | 10720490 | Oedema | |
| 107204907 | 10720490 | Second primary malignancy | |
| 107204907 | 10720490 | Uterine cancer |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 107204907 | 10720490 | 1 | 20100225 | 0 | ||
| 107204907 | 10720490 | 2 | 20100218 | 20100308 | 0 |